Filing Analysis
📄 Other SEC Filing
Filed Jul 17, 2026
⚪ LOW
Polaryx Therapeutics, Inc. announced the date for its 2026 Annual Meeting of Stockholders, which is scheduled to be held virtually on September 10, 2026.
🚩 Red Flags
- Company did not hold an annual meeting during 2025 (potential indicator of administrative or regulatory issues, though common in some micro-caps).
📋 Key Facts
- The 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026.
- The record date for stockholders entitled to notice and vote at the meeting is July 27, 2026.
- Stockholder proposals under Rule 14a-8 must be received by the company by the close of business on July 27, 2026.
- The company did not hold an annual meeting in 2025.
💸 Securities Offering
Filed May 28, 2026
⚪ LOW
Polaryx Therapeutics entered into a Securities Purchase Agreement on May 27, 2026, to raise $10 million in gross proceeds through a private placement of 2,502,696 shares of common stock.
📋 Key Facts
- Gross proceeds: $10 million
- Shares issued: 2,502,696 shares of common stock
- Weighted average price per share: approximately $4.00
- Price range: $3.70 to $4.10 per share based on commitment level
- Dilution: Approximately 5.3% of outstanding shares prior to the placement
- Largest stockholder, MStone Partners Healthcare Limited, participated with a purchase of 88,453 shares for $360,000
- Use of proceeds: Funding the Phase 2 SOTERIA (PLX-200-600) proof-of-concept basket trial, working capital, and general corporate purposes
- Closing date: May 28, 2026
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.